Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biotechnology company built on RNA interference, a technique that switches off the genes behind certain diseases.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 1,987,407 | $598,269,130 | +49% | 2.06% |
| 2. | D E Shaw D. E. Shaw | 1,104,109 | $332,369,932 | +5% | 0.16% |
| 3. | Deep Track Capital David Kroin | 825,000 | $248,349,750 | 3.61% | |
| 4. | AQR Capital Management Cliff Asness | 728,039 | $218,994,064 | -21% | 0.08% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 482,751 | $145,322,534 | +88% | 0.34% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.67 | 4 | $1,210.68 | 36 | 2024-10-17 | Filing | |
| $286.00 | 32 | $9,152.00 | 32 | 2024-08-29 | Filing | |
| $71.87 | 297,501 | $21,381,396.87 | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | $751,502.00 | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | $1,032,327.90 | 27,900 | 2016-10-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $226.88 | 1,758 | $398,855.04 | 12,807 | 2026-10-02 | Filing | |
| $302.65 | 17 | $5,145.05 | 1,582 | 2026-06-01 | Filing | |
| $300.72 | 495 | $148,856.40 | 1,599 | 2026-06-01 | Filing | |
| $299.87 | 1,222 | $366,441.14 | 2,094 | 2026-06-01 | Filing | |
| $298.91 | 1,175 | $351,219.25 | 3,316 | 2026-06-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 168,320 | $41,531,277 | 0.04% | |
| 2. | 14,813,000 | $16,039,422 | 0.58% | |
| 3. | 63,231 | $15,601,616 | 0.08% | |
| 4. | 59,700 | $14,730,378 | 0.83% | |
| 5. | 31,675 | $7,815,490 | 0.05% |
News See All
9 New Contenders for S&P 500 Index
Joining the S&P 500 is one of the clearest signs that a company has arrived.
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?
Is ALNY a good stock to buy? We came across a bullish thesis on Alnylam Pharmaceuticals, Inc. on Astute Optics - US’s Substack.
Overvalued Healthcare Stocks? Analysts See Upside in These 3 High P/E Names
Using the TipRanks Stock Screener tool, we identified three Healthcare stocks with P/E ratios ranging from 39.58x to 43.34x, Strong ...
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”.
Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks
The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has...
Why Alnylam's Best Quarter Ever Didn't Come With a Richer Valuation
2026 has marked a significant turning point in biotech capital markets, not just a small comeback.
10 Best Growth Stocks With Highest Upside Potential
In this article, we will look at the 10 Best Growth Stocks With Highest Upside Potential.
What Offers Alnylam Pharmaceuticals (ALNY) Sustained Long-Term Growth?
Brown Advisory, an investment management company, released its “Brown Large-Cap Growth Strategy” for the first-quarter 2026 investor letter. A copy of the letter is available to download here.
10 Best Fundamentally Strong Stocks to Buy for Long Term
In this article, we will discuss: 10 Best Fundamentally Strong Stocks to Buy for Long Term.
Hedge Fund Resource Center